Clinical Trials

477 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07283939 2026-04-07

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

420 enrolled

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT04703101 2026-03-30

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Phase 1 Recruiting

25 enrolled

Rectal Neoplasms

NCT05806931 2026-03-18

SCOTI

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

49 enrolled

Rectal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Rectal Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

170 enrolled

Rectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

26 enrolled

Rectal Neoplasms

NCT06204094 2025-01-07

CASINOs

37 enrolled

Rectal Neoplasms

NCT05000697 2024-11-27

CCHOWW

216 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05424692 2024-11-04

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

200 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT06455124 2024-06-13

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

60 enrolled

Rectal Neoplasms

NCT06266832 2024-02-20

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

30 enrolled

Rectal Neoplasms

NCT06017583 2023-10-11

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

48 enrolled

Rectal Neoplasms

NCT05877573 2023-07-05

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

53 enrolled

Rectal Neoplasms

NCT05201430 2022-03-04

RCNAC

300 enrolled